Alzheimer: A decade of drug design. Why molecular topology can be an extra edge.

about

Alzheimer: A decade of drug design. Why molecular topology can be an extra edge.

Item

http://www.wikidata.org/entity/Q49496422

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Alzheimer: A decade of drug design. Why molecular topology can be an extra edge.

@en

Alzheimer: A decade of drug design. Why molecular topology can be an extra edge.

@nl

type

Item

label

Alzheimer: A decade of drug design. Why molecular topology can be an extra edge.

@en

Alzheimer: A decade of drug design. Why molecular topology can be an extra edge.

@nl

prefLabel

Alzheimer: A decade of drug design. Why molecular topology can be an extra edge.

@en

Alzheimer: A decade of drug design. Why molecular topology can be an extra edge.

@nl

P1476

Alzheimer: A decade of drug design. Why molecular topology can be an extra edge.

@en

P2093

Jorge Galvez

http://www.w3.org/2001/XMLSchema#string

Ramon Garcia-Domenech

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Molecular topology as novel strategy for discovery of drugs with aβ lowering and anti-aggregation dual activities for Alzheimer's disease

Treatment for Alzheimer's disease: has anything changed?

A 3D-QSAR model based screen for dihydropyridine-like compound library to identify inhibitors of amyloid beta (Aβ) production.

In silico investigation of traditional Chinese medicine compounds to inhibit human histone deacetylase 2 for patients with Alzheimer's disease.

Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids

Exploring the binding of BACE-1 inhibitors using comparative binding energy analysis (COMBINE).

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

Structure based design, synthesis, pharmacophore modeling, virtual screening, and molecular docking studies for identification of novel cyclophilin D inhibitors.

Development of dual inhibitors against Alzheimer's disease using fragment-based QSAR and molecular docking.

Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers.

P31

scholarly article

review article

P356

10.2174/1570159X15666171129102042

http://www.w3.org/2001/XMLSchema#string

P50

Riccardo Zanni

Maria Galvez-Llompart

P5008

ScienceSource

P577

2017-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29189164

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

molecular design

biomedical investigative technique

P932

6080094

http://www.w3.org/2001/XMLSchema#string